Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Inherit Metab Dis ; 31(1): 81-7, 2008 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-18214711

RESUMO

We describe a retrospective study of long-term outcome of 46 patients treated and regularly followed in France with 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione (NTBC) for tyrosinaemia type I. Most had initial good response with normalization of liver function and metabolic parameters. Only one infant had no response to treatment and required liver transplantation. Among the 45 long-term treated patients, three underwent secondary liver transplantation: one for cirrhosis and two because of hepatocellular carcinoma. One of the latter died of transplantation complications, so that the overall survival rate was 97.5%. However, 17 of 45 showed persistent abnormal liver imaging (heterogeneous liver) and 6 had cirrhosis. Furthermore, 15 had persistently elevated levels of alpha-fetoprotein, highlighting the question of the persistent risk of carcinoma. Quality of life was usually good but compliance problems were frequent, mainly regarding the low phenylalanine-tyrosine diet. Few adverse effects were observed. A main concern was the high frequency of cognitive impairment causing schooling problems, which may be related to persistent chronic hypertyrosinaemia. In conclusion, this series confirms that NTBC treatment has clearly improved the vital prognosis and quality of life of tyrosinaemia type I patients but that many late complications persist. Long-term studies are necessary to determine whether this drug may prevent or only delay liver complications, andto survey the possible risks of the drug. A more restricted diet could be necessary to prevent the neurological impact of the disease.


Assuntos
Cicloexanonas/uso terapêutico , Nitrobenzoatos/uso terapêutico , Tirosinemias/tratamento farmacológico , Pré-Escolar , Cicloexanonas/efeitos adversos , Inibidores Enzimáticos/efeitos adversos , Inibidores Enzimáticos/uso terapêutico , Seguimentos , França , Humanos , Lactente , Recém-Nascido , Fígado/fisiologia , Testes de Função Hepática , Nitrobenzoatos/efeitos adversos , Cooperação do Paciente , Estudos Retrospectivos , Fatores de Tempo , Falha de Tratamento , Tirosinemias/fisiopatologia
2.
Am J Hum Genet ; 68(4): 839-47, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11231903

RESUMO

Dimethylglycine dehydrogenase (DMGDH) (E.C. number 1.5.99.2) is a mitochondrial matrix enzyme involved in the metabolism of choline, converting dimethylglycine to sarcosine. Sarcosine is then transformed to glycine by sarcosine dehydrogenase (E.C. number 1.5.99.1). Both enzymes use flavin adenine dinucleotide and folate in their reaction mechanisms. We have identified a 38-year-old man who has a lifelong condition of fishlike body odor and chronic muscle fatigue, accompanied by elevated levels of the muscle form of creatine kinase in serum. Biochemical analysis of the patient's serum and urine, using (1)H-nuclear magnetic resonance NMR spectroscopy, revealed that his levels of dimethylglycine were much higher than control values. The cDNA and the genomic DNA for human DMGDH (hDMGDH) were then cloned, and a homozygous A-->G substitution (326 A-->G) was identified in both the cDNA and genomic DNA of the patient. This mutation changes a His to an Arg (H109R). Expression analysis of the mutant cDNA indicates that this mutation inactivates the enzyme. We therefore confirm that the patient described here represents the first reported case of a new inborn error of metabolism, DMGDH deficiency.


Assuntos
Erros Inatos do Metabolismo/enzimologia , Erros Inatos do Metabolismo/genética , Oxirredutases N-Desmetilantes/deficiência , Oxirredutases N-Desmetilantes/genética , Mutação Puntual/genética , Sarcosina/análogos & derivados , Adulto , Sequência de Aminoácidos , Substituição de Aminoácidos/genética , Sequência de Bases , População Negra/genética , Western Blotting , Linhagem Celular , Doença Crônica , Clonagem Molecular , Creatina Quinase/sangue , Análise Mutacional de DNA , Dimetilglicina Desidrogenase , Etiquetas de Sequências Expressas , Fadiga/complicações , Fadiga/enzimologia , Fadiga/genética , Fadiga/metabolismo , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Erros Inatos do Metabolismo/complicações , Erros Inatos do Metabolismo/metabolismo , Mitocôndrias/enzimologia , Proteínas Mitocondriais , Dados de Sequência Molecular , Odorantes , Oxirredutases N-Desmetilantes/química , Fenótipo , Sarcosina/sangue , Sarcosina/urina
3.
Clin Chem ; 45(4): 459-64, 1999 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-10102904

RESUMO

BACKGROUND: A38-year-old man presented with a history of fish odor (since age 5) and unusual muscle fatigue with increased serum creatine kinase. Our aim was to identify the metabolic error in this new condition. METHODS: We used 1H NMR spectroscopy to study serum and urine from the patient. RESULTS: The concentration of N, N-dimethylglycine (DMG) was increased approximately 100-fold in the serum and approximately 20-fold in the urine. The presence of DMG as a storage product was confirmed by use of 13C NMR spectroscopy and gas chromatography-mass spectrometry. The high concentration of DMG was caused by a deficiency of the enzyme dimethylglycine dehydrogenase (DMGDH). A homozygous missense mutation was found in the DMGDH gene of the patient. CONCLUSIONS: DMGDH deficiency must be added to the differential diagnosis of patients complaining of a fish odor. This deficiency is the first inborn error of metabolism discovered by use of in vitro 1H NMR spectroscopy of body fluids.


Assuntos
Erros Inatos do Metabolismo/enzimologia , Oxirredutases N-Desmetilantes/genética , Adulto , Dimetilglicina Desidrogenase , Cromatografia Gasosa-Espectrometria de Massas , Humanos , Espectroscopia de Ressonância Magnética , Masculino , Erros Inatos do Metabolismo/sangue , Erros Inatos do Metabolismo/fisiopatologia , Erros Inatos do Metabolismo/urina , Proteínas Mitocondriais , Mutação de Sentido Incorreto , Odorantes , Oxirredutases N-Desmetilantes/deficiência , Oxirredutases N-Desmetilantes/urina , Sarcosina/análogos & derivados , Sarcosina/urina
4.
Ann Fr Anesth Reanim ; 15(7): 1037-40, 1996.
Artigo em Francês | MEDLINE | ID: mdl-9180981

RESUMO

OBJECTIVE: As hydratation of the normal brain is much more dictated by osmotic gradients than by hydrostatic or oncotic pressures, this study aimed to compare the effect of the infusion of currently used volume loading solutions on plasma osmolality. STUDY DESIGN: Randomized, comparative trial. PATIENTS: Thirty ASA 1-2 patients, scheduled for lumbar intervertebral disc surgery were randomly allocated to three groups receiving either 2,000 mL of lactated Ringer's solution (RL, n = 10), 750 mL of hydroxyethylstarch 6% (HEA, n = 10) or 2,000 mL of normal saline (NaCl, n = 10). METHODS: Baseline osmolality, natraemia, glycaemia and protidaemia were measured before induction of anaesthesia (T1), after the infusion of 375 mL of hydroxyethylstarch or 1,000 mL of crystalloids (T2) and at the end of the infusion (T3). RESULTS: The three groups were identical for age, weight, initial plasma osmolality and natraemia. However, osmolality in the RL group was decreased at T2 and T3 compared to T1 (respectively: 299 +/- 5 mOsm.kg-1, 295 +/- 4 mOsm.kg-1 and 292 +/- 5 mOsm.kg-1. Osmolality at T2 and T3 was also lower in the RL group compared to the HEA and NaCl groups (respectively: 301 +/- 6 mOsm.kg-1 and 304 +/- 13 mOsm.kg-1 for T2 and T3 in the HEA group, and 299 +/- 5 mOsm.kg-1 and 298 +/- 5 mOsm.kg-1 in the NaCl group). In the HEA and NaCl groups, osmolality was unchanged at T2 and T3 compared to T1. CONCLUSION: Both normal saline and hydroxyethylstarch 6% maintain plasma osmolality, whereas Ringer lactate tends to decrease it. For that reason normal saline and hetastarch 6% but not lactated Ringer's solution, may be administered in patients experiencing blood-brain barrier damage.


Assuntos
Substitutos do Plasma/farmacologia , Volume Plasmático/efeitos dos fármacos , Glicemia/análise , Humanos , Derivados de Hidroxietil Amido/farmacologia , Concentração Osmolar , Pressão Osmótica/efeitos dos fármacos , Solução Salina Hipertônica/farmacologia , Sódio/sangue
5.
J Clin Invest ; 93(6): 2514-8, 1994 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8200987

RESUMO

We report an inborn error of the tricarboxylic acid cycle, fumarase deficiency, in two siblings born to first cousin parents. They presented with progressive encephalopathy, dystonia, leucopenia, and neutropenia. Elevation of lactate in the cerebrospinal fluid and high fumarate excretion in the urine led us to investigate the activities of the respiratory chain and of the Krebs cycle, and to finally identify fumarase deficiency in these two children. The deficiency was profound and present in all tissues investigated, affecting the cytosolic and the mitochondrial fumarase isoenzymes to the same degree. Analysis of fumarase cDNA demonstrated that both patients were homozygous for a missense mutation, a G-955-->C transversion, predicting a Glu-319-->Gln substitution. This substitution occurred in a highly conserved region of the fumarase cDNA. Both parents exhibited half the expected fumarase activity in their lymphocytes and were found to be heterozygous for this substitution. The present study is to our knowledge the first molecular characterization of tricarboxylic acid deficiency, a rare inherited inborn error of metabolism in childhood.


Assuntos
Encefalopatias/genética , Erros Inatos do Metabolismo dos Carboidratos/genética , Fumarato Hidratase/deficiência , Fumarato Hidratase/genética , Sequência de Aminoácidos , Ciclo do Ácido Cítrico , DNA Complementar/química , Feminino , Humanos , Recém-Nascido , Masculino , Dados de Sequência Molecular , Mutação
6.
Biol Neonate ; 62(1): 37-46, 1992.
Artigo em Inglês | MEDLINE | ID: mdl-1391274

RESUMO

The ability for 18-day fetal rat hepatocytes in primary culture to modify extracellular amino acid concentrations was studied between 24 and 48 h of culture. Most of the 19 amino acids tested were found to be taken up by the hepatocytes. However, serine and glutamate appeared in the 24-hour-conditioned medium to be twice as concentrated as in the fresh medium. The profile of net consumption or production of amino acids was unchanged when the medium was supplemented with essential amino acids. The use of [U-14C]glucose revealed that serine released in the medium was mainly formed from glucose. The presence of insulin (10 nM) did neither significantly modify the variations of amino acid concentrations in the medium nor 2-amino[1-14C]isobutyric acid uptake by the cells, while the hormone produced a 2-fold increase in glycogen labeling from [U-14C]glucose. This study revealed that whatever the regulatory culture conditions considered a net serine production out of the cells occurred, which appears to be specific to the fetal stage.


Assuntos
Aminoácidos/metabolismo , Fígado/metabolismo , Aminoácidos/biossíntese , Ácidos Aminoisobutíricos/metabolismo , Animais , Transporte Biológico Ativo/efeitos dos fármacos , Células Cultivadas , Glucose/metabolismo , Insulina/farmacologia , Lactatos/biossíntese , Ácido Láctico , Fígado/efeitos dos fármacos , Glicogênio Hepático/biossíntese , Ratos , Serina/biossíntese
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...